MOMasahiko Oka

Masahiko Oka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masahiko Oka has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Ivan F. McMurtry

    Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama

    3 shared publications
  • Kohtaro Abe

    Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama

    3 shared publications
  • Abdallah Alzoubi

    Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan

    2 shared publications
  • Hiroki Ota

    Departments of Pharmacology

    2 shared publications
  • Masako Ito

    Departments of Pharmacology

    2 shared publications
  • Michie Toba

    Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama

    2 shared publications

Latest Publications

  • Open Access

    A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension

    by Michie Toba, Abdallah Alzoubi, Kealan O’nEill, Kohtaro Abe, Takeo Urakami, Masanobu Komatsu, Diego Alvarez, Tero A.H. Järvinen, David Mann, Erkki Ruoslahti, et al.


  • Open Access

    Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension

    by Moloud Rabieyousefi, Pejman Soroosh, Kimio Satoh, Fumiko Date, Naoto Ishii, Masahiro Yamashita, Masahiko Oka, Ivan F McMurtry, Hiroaki Shimokawa, Masato Nose, et al.

    Pulmonary hypertension (PH) refers to a spectrum of diseases with elevated pulmonary artery pressure. Pulmonary arterial hypertension (PAH) is a disease category that clinically presents with severe PH and that is histopathologically characterized by the occlusion of pulmonary arterioles, medial muscular hypertrophy, and/or intimal fibrosis. PAH occurs with a secondary as well as a primary onset. Secondary PAH is known to be complicated with immunological disorders. The aim of the present study is to histopathologically and genetically characterize a new animal model of PAH and clarify the role of OX40 ligand in the pathogenesis of PAH. Spontaneous onset of PAH was stably identified in mice with immune abnormality because of overexpression of the tumor necrosis factor (TNF) family molecule OX40 ligand (OX40L). Histopathological and physical examinations revealed the onset of PAH-like disorders in the C57BL/6 (B6) strain of OX40L transgenic mice (B6.TgL). Comparative analysis performed using different strains of transgenic mice showed that this onset depends on the presence of OX40L in the B6 genetic background. Genetic analyses demonstrated a susceptibility locus of a B6 allele to this onset on chromosome 5. Immunological analyses revealed that the excessive OX40 signals in TgL mice attenuates expansion of regulatory T cells the B6 genetic background, suggesting an impact of the B6 genetic background on the differentiation of regulatory T cells. Present findings suggest a role for the OX40L-derived immune response and epistatic genetic effect in immune-mediated pathogenesis of PAH.


  • Tyrosine Kinase Inhibitors Are Potent Acute Pulmonary Vasodilators in Rats

    by Kohtaro Abe, Michie Toba, Abdallah Alzoubi, Karel Koubsky, Masako Ito, Hiroki Ota, Salina Gairhe, William T. Gerthoffer, Karen A. Fagan, Ivan F. McMurtry, et al.

    Tyrosine kinase inhibitors are promising for the treatment of severe pulmonary hypertension. Their therapeutic effects are postulated to be due to inhibition of cell growth–related kinases and attenuation of vascular remodeling. Their potential vasodilatory activities have not been explored. Vasorelaxant effects of the tyrosine kinase inhibitors imatinib, sorafenib, and nilotinib were examined in isolated pulmonary arterial rings from normal and pulmonary hypertensive rats. Phosphorylation of myosin light chain phosphatase and myosin light chain was assessed by Western blots. Acute hemodynamic effects of imatinib were tested in the pulmonary hypertensive rats. In normal pulmonary arteries, imatinib reversed serotonin- and U46619-induced contractions in a concentration-dependent and endothelium-independent manner. Sorafenib and nilotinib relaxed U46619-induced contraction. Imatinib inhibited activation of myosin phosphatase induced by U46619 in normal pulmonary arteries. All three tyrosine kinase inhibitors concentration-dependently and completely reversed the spontaneous contraction of hypertensive pulmonary arterial rings unmasked by inhibition of nitric oxide synthase. Acute intravenous administration of imatinib reduced high right ventricular systolic pressure in pulmonary hypertensive rats, with little effect on left ventricular systolic pressure and cardiac output. We conclude that tyrosine kinase inhibitors have potent pulmonary vasodilatory activity, which could contribute to their long-term beneficial effect against pulmonary hypertension. Vascular smooth muscle relaxation mediated via activation of myosin light chain phosphatase (Ca2+ desensitization) appears to play a role in the imatinib-induced pulmonary vasodilation.


  • Open Access

    S1P4Receptor Mediates S1P‐Induced Vasoconstriction in Normotensive and Hypertensive Rat Lungs

    by Hiroki Ota, Michelle A. Beutz, Masako Ito, Kohtaro Abe, Masahiko Oka, Ivan F. McMurtry

    This study aimed to identify receptors mediating sphingosine‐1‐phosphate (S1P)‐induced vasoconstriction in the normotensive and chronic hypoxia‐induced hypertensive rat pulmonary circulation. In isolated perfused lungs from normoxic rats, infusion of S1P caused a sustained vasoconstriction, which was not reduced by combinational pretreatment with the dual S1P1 and 3receptor antagonist VPC23019 and the S1P2receptor antagonist JTE013. The S1P4receptor agonists phytosphingosine‐1‐phospate and VPC23153, but not the dual S1P1 and 3receptor agonist VPC24191, caused dose‐dependent vasoconstrictions. In hypertensive lungs from chronically hypoxic rats, the vasoconstrictor responses to S1P and VPC23153 were markedly enhanced. The S1P4receptor agonist VPC 23153 caused contraction of isolated pulmonary but not of renal or mesenteric arteries from chronically hypoxic rats. S1P4receptor protein as well as mRNA were detected in both normotensive and hypertensive pulmonary arteries. In contrast to what has been reported in the systemic circulation and mouse lung, our findings raise the possibility that S1P4receptor plays a significant role in S1P‐induced vasoconstriction in the normotensive and hypertensive rat pulmonary circulation.


  • Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension

    by M Oka, K A Fagan, P L Jones, I F McMurtry

    A burgeoning body of evidence suggests that RhoA/Rho kinase (ROCK) signalling plays an important role in the pathogenesis of various experimental models of pulmonary hypertension (PH), including chronic hypoxia‐, monocrotaline‐, bleomycin‐, shunt‐ and vascular endothelial growth factor receptor inhibition plus chronic hypoxia‐induced PH. ROCK has been incriminated in pathophysiologic events ranging from mediation of sustained abnormal vasoconstriction to promotion of vascular inflammation and remodelling. In addition, the 3‐hydoxy‐3‐methylglutaryl CoA reductase inhibitors, statins, which inhibit activation of RhoA by preventing post‐translational isoprenylation of the protein and its translocation to the plasma membrane ameliorate PH in several different rat models, and may also be effective in PH patients. Also, phosphorylation of RhoA and prevention of its translocation to the plasma membrane are involved in the protective effect of the type 5‐PDE inhibitor, sildenafil, against hypoxia‐ and bleomycin‐induced PH. Collectively, these and other observations indicate that independent of the cause of PH, activation of the RhoA/ROCK pathway serves as a point of convergence of various signalling cascades in the pathogenesis of the disease. We propose that ROCK inhibitors and other drugs that inhibit this pathway might be useful in the treatment of various forms of PH.British Journal of Pharmacology (2008) 155, 444–454; doi:10.1038/bjp.2008.239; published online 9 June 2008